Asthma and COPD Drugs Market Highlights
Global Asthma and COPD Drugs Market size are expected to register a CAGR of 7.90% during the forecast period with a market value of USD 43,444.72 Million till 2025. Asthma is a type of inflammatory disease that affects the lungs and makes breathing difficult. It is one of the common chronic condition affecting many people across the globe. COPD or chronic obstructive pulmonary disease is an umbrella term used for a group of respiratory diseases such as emphysema and chronic bronchitis.
Asthma and COPD Drugs Market Segmentation
The Global Asthma and COPD Drugs Market have been segmented by disease, product, route of administration, and distribution channel. The market, based on disease, has been bifurcated into asthma and COPD.
The quick-relief medications have been further segmented into short-acting beta-agonists, oral & intravenous corticosteroids, ipratropium bromide (Atrovent), and others. Short-acting beta-agonists have been further segregated into Proair and Ventolin.
Global asthma and COPD drugs market, based on the route of administration, has been segmented into oral, inhaled, and others. On the basis of the distribution channels, global asthma and COPD drugs market has been segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
Asthma and COPD Drugs Market Regional Analysis
Global asthma and COPD drugs market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas are likely to dominate global asthma and COPD drugs market. This can be attributed to the rising patient population suffering from asthma and COPD in the region. According to the American Academy of Allergy Asthma & Immunology, in 2016, approximately 8.3% of children in the US had asthma. Moreover, the rising health expenditure per person and increasing demand for advanced treatment options are also expected to drive market growth.
Asia-Pacific is estimated to be the fastest-growing market owing to the rising awareness regarding COPD and asthma in the region. For instance, Koninklijke Philips launched a campaign in May 2019, for raising
Awareness of asthma in India on World Asthma Day. Moreover, a high prevalence of asthma and COPD is also positively affecting the market growth.
The market in the Middle East & Africa is expected to witness steady growth due to the rising patient population suffering from asthma and COPD in the Middle Eastern countries.
Asthma and COPD Drugs Market Key Players
MRFR recognizes the following companies as the Key Players in the Global Asthma and COPD Drugs Market— GlaxoSmithKline plc (UK), AstraZeneca (UK), Boehringer Ingelheim International GmbH (Germany), and Chiesi Farmaceutici SpA (Italy).
Asthma and COPD Drugs Market Key Findings
The Global Asthma and COPD Drugs Market is estimated to reach USD 43,444.72 Million by 2025 at a CAGR of 7.90% during the assessment period
The Americas accounted for the largest share of the global asthma and COPD drugs market due to the increasing incidence rate of asthma and COPD
Based on disease, the COPD segment accounted for the largest Asthma and COPD Drugs Market share of 61.29% in 2018
Based on product, the long-term asthma control medications segment accounted for the largest Asthma and COPD Drugs Market share of 83.01% in 2018
Based on route of administration, the inhaled drugs segment accounted for the largest Asthma and COPD Drugs Market share of 53.53% in 2018
Based on distribution channel, the retail pharmacies segment accounted for the largest Asthma and COPD Drugs Market share of 49.88% in 2018

https://www.marketresearchfuture.com/reports/asthma-copd-drugs-market-8749